相关实验视频
Updated: Jul 6, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
在用静脉注射常规胰岛素治疗高血糖症期间评估患低血糖症的危险因素
Meghan M Beard1, Jeffrey J McKenzie1, Terry G Potter1
1Department of Pharmacy Services, Virginia Commonwealth University Health System, Richmond, VA, USA.
Journal of pharmacy practice
|January 5, 2024
概括
与常规剂量相比,静脉注射常规胰岛素用于高血糖症的基于体重的剂量并没有显著改变低血糖风险或的降低. 其他因素,如女性的性别和较低的基线葡萄糖预测低血糖.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内部医学 内部医学
背景情况:
- 常规的10单位静脉注射 (IV) 常规胰岛素治疗高血糖症与低血糖症有关.
- 基于体重的相对于传统的IV胰岛素剂量的比较疗效和安全性需要进一步确定.
研究的目的:
- 为了比较基于体重的IV常规胰岛素剂量,在患有低血糖症和没有患有低血糖症的患者之间.
- 评估基于体重的剂量对低血糖发病率和高血糖治疗中的减少的影响.
主要方法:
- 在一个单一的学术医疗中心进行回顾性电子图表审查.
- 纳入标准:患者≥18岁,接受IV常规胰岛素治疗6小时内≥5mmol/L.
主要成果:
- 低血糖和非低血糖组之间基于体重的胰岛素剂量 (0.14对0.22单位/kg) 没有显著差异 (P = .44).
- 在两组中都观察到类似的降效应 (1.02对0.96 mmol/L) (P = .56).
- 低血糖的独立风险因素包括女性性别,基线低血糖 (<140 mg/dL) 和重复服用胰岛素.
结论:
- 基于体重的IV常规胰岛素剂量没有显示出低血糖事件或减少的差异.
- 女性性别,基线低血糖和重复剂量被确定为低血糖的预测因素.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
176
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
176
Hypoglycemia and Glucagon
264
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
264
Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
Diabetes: Symptoms, Diagnosis, and Complications
549
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
549
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Insulin Formulations: Types and Delivery
197
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
197

